GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Humedix Co 200670.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

21,900

+0.23%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Humedix Co

Its shares trade on KOSDAQ under the ticker 200670.KQ. It has been listed since 26 December 2014. In the fiscal year to 31 December 2025, it reported revenue of ₩170.05bn and net income of ₩51.79bn. At that date it held total assets of ₩323.64bn and shareholders' equity of ₩299.59bn.

Humedix Co., Ltd. engages in the manufacture and sale of hyaluronic acid based medical devices and arthritis treatment products. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2014-12-26. The firm distributes its products within domestic market and to overseas markets

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
26 Dec 2014
Employees
338
Website
humedix.com ↗

Leadership

Pay as last reported

  • Jin Hwan KimChief Executive Officer, Director, since 2017
  • Yim Seong LeeInternal Auditor
  • Bong Su KimDirector
  • Dong Cheol SonDirector
  • Myeong Su LeeNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Humedix Co Ltd manufactures hyaluronic acid medical devices in Seongnam, KR.
  • The company employs 338 full-time staff in the Health Care sector.
  • Humedix distributes arthritis treatment products domestically and internationally.

Weaknesses

  • Humedix has no domestic market presence beyond Seongnam, KR.
  • The company's products are limited to hyaluronic acid based medical devices.
  • Humedix's IPO was in 2014, showing limited recent market activity.

Opportunities

  • Humedix can expand arthritis treatment products into the European market.
  • The global Health Care sector offers growth for hyaluronic acid medical devices.
  • Humedix may increase sales in the Asian market for arthritis treatments.

Threats

  • Humedix faces competition from other Korean pharmaceutical companies.
  • The Health Care industry has strict regulatory requirements in KR.
  • Humedix must comply with international medical device regulations for overseas markets.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.